217 related articles for article (PubMed ID: 33010112)
1. Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).
Okano N; Furuse J; Ueno M; Morizane C; Yamanaka T; Ojima H; Ozaka M; Sasaki M; Takahara N; Nakai Y; Kobayashi S; Morimoto M; Hosoi H; Maeno S; Nagashima F; Ikeda M; Okusaka T
Oncologist; 2021 Feb; 26(2):97-e201. PubMed ID: 33010112
[TBL] [Abstract][Full Text] [Related]
2. Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases.
Okano N; Kasuga A; Kawai K; Kobayashi T; Naruge D; Nagashima F; Furuse J
Anticancer Res; 2017 Jul; 37(7):3711-3715. PubMed ID: 28668864
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
4. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
6. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
Ioka T; Kanai M; Kobayashi S; Sakai D; Eguchi H; Baba H; Seo S; Taketomi A; Takayama T; Yamaue H; Takahashi M; Sho M; Kamei K; Fujimoto J; Toyoda M; Shimizu J; Goto T; Shindo Y; Yoshimura K; Hatano E; Nagano H;
J Hepatobiliary Pancreat Sci; 2023 Jan; 30(1):102-110. PubMed ID: 35900311
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
9. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy.
Lee S; Shroff RT; Makawita S; Xiao L; Danner De Armas A; Bhosale P; Reddy K; Shalaby A; Raghav K; Pant S; Wolff RA; Javle M
Clin Cancer Res; 2022 Jun; 28(11):2229-2236. PubMed ID: 35312753
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
12. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
Chen X; Wu X; Wu H; Gu Y; Shao Y; Shao Q; Zhu F; Li X; Qian X; Hu J; Zhao F; Mao W; Sun J; Wang J; Han G; Li C; Xia Y; Seesaha PK; Zhu D; Li H; Zhang J; Wang G; Wang X; Li X; Shu Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33172881
[TBL] [Abstract][Full Text] [Related]
13. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Choi IS; Kim KH; Lee JH; Suh KJ; Kim JW; Park JH; Kim YJ; Kim JS; Kim JH; Kim JW
Eur J Cancer; 2021 Sep; 154():288-295. PubMed ID: 34303267
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer.
Kobayashi S; Ueno M; Sugimori K; Morizane C; Kojima Y; Irie K; Goda Y; Morimoto M; Ohkawa S
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1189-1196. PubMed ID: 29071413
[TBL] [Abstract][Full Text] [Related]
15. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
Iyer RV; Pokuri VK; Groman A; Ma WW; Malhotra U; Iancu DM; Grande C; Saab TB
Am J Clin Oncol; 2018 Jul; 41(7):649-655. PubMed ID: 27849649
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
[TBL] [Abstract][Full Text] [Related]
17. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.
Jung K; Park J; Jung JH; Lee JC; Kim J; Hwang JH
Gut Liver; 2022 Sep; 16(5):798-805. PubMed ID: 35000934
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.
Park I; Lee HJ; Bae WK; Yoon S; Lee JL
Invest New Drugs; 2019 Dec; 37(6):1239-1246. PubMed ID: 31231787
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.
Bondarenko IM; Ingrosso A; Bycott P; Kim S; Cebotaru CL
BMC Cancer; 2015 May; 15():339. PubMed ID: 25929582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]